JP2012526850A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012526850A5 JP2012526850A5 JP2012511031A JP2012511031A JP2012526850A5 JP 2012526850 A5 JP2012526850 A5 JP 2012526850A5 JP 2012511031 A JP2012511031 A JP 2012511031A JP 2012511031 A JP2012511031 A JP 2012511031A JP 2012526850 A5 JP2012526850 A5 JP 2012526850A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- dependent kinase
- cdk4
- use according
- cyclin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims 20
- 102000013698 Cyclin-Dependent Kinase 6 Human genes 0.000 claims 20
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 claims 20
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 9
- 239000012623 DNA damaging agent Substances 0.000 claims 8
- 239000003638 chemical reducing agent Substances 0.000 claims 7
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 6
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 6
- 231100000419 toxicity Toxicity 0.000 claims 6
- 230000001988 toxicity Effects 0.000 claims 6
- 239000003102 growth factor Substances 0.000 claims 5
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 4
- 102000015696 Interleukins Human genes 0.000 claims 4
- 108010063738 Interleukins Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 102000003951 Erythropoietin Human genes 0.000 claims 3
- 108090000394 Erythropoietin Proteins 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 229940105423 erythropoietin Drugs 0.000 claims 3
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 3
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 claims 2
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 claims 2
- 229940083347 Cyclin-dependent kinase 4 inhibitor Drugs 0.000 claims 2
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 claims 2
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 claims 2
- 102000015215 Stem Cell Factor Human genes 0.000 claims 2
- 108010039445 Stem Cell Factor Proteins 0.000 claims 2
- 102000036693 Thrombopoietin Human genes 0.000 claims 2
- 108010041111 Thrombopoietin Proteins 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000009437 off-target effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 238000011084 recovery Methods 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 210000000601 blood cell Anatomy 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 231100001157 chemotherapeutic toxicity Toxicity 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000012010 growth Effects 0.000 claims 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 1
- 230000011132 hemopoiesis Effects 0.000 claims 1
- 230000005865 ionizing radiation Effects 0.000 claims 1
- 108010048732 pegylated erythropoietin Proteins 0.000 claims 1
- 230000006320 pegylation Effects 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17772409P | 2009-05-13 | 2009-05-13 | |
| US61/177,724 | 2009-05-13 | ||
| PCT/US2010/034816 WO2010132725A2 (en) | 2009-05-13 | 2010-05-13 | Cyclin dependent kinase inhibitors and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012526850A JP2012526850A (ja) | 2012-11-01 |
| JP2012526850A5 true JP2012526850A5 (OSRAM) | 2013-06-27 |
Family
ID=43085590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012511031A Pending JP2012526850A (ja) | 2009-05-13 | 2010-05-13 | サイクリン依存性キナーゼ阻害剤及びその用法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20120100100A1 (OSRAM) |
| EP (4) | EP3025724B1 (OSRAM) |
| JP (1) | JP2012526850A (OSRAM) |
| CN (1) | CN102458443A (OSRAM) |
| AU (1) | AU2010248886A1 (OSRAM) |
| CA (1) | CA2761896A1 (OSRAM) |
| ES (1) | ES2561216T3 (OSRAM) |
| IL (1) | IL216315A0 (OSRAM) |
| WO (1) | WO2010132725A2 (OSRAM) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102231984A (zh) * | 2008-10-01 | 2011-11-02 | 北卡罗来纳大学查珀尔希尔分校 | 使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗化疗化合物的造血防护 |
| JP2012504645A (ja) * | 2008-10-01 | 2012-02-23 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | 健康な細胞に対する電離放射線の影響を低下させる又は防止するための医薬組成物 |
| WO2010132725A2 (en) | 2009-05-13 | 2010-11-18 | The University Of North Carolina At Chapel Hill | Cyclin dependent kinase inhibitors and methods of use |
| LT2632467T (lt) | 2010-10-25 | 2016-09-12 | G1 Therapeutics, Inc. | Cdk inhibitoriai |
| US8691830B2 (en) | 2010-10-25 | 2014-04-08 | G1 Therapeutics, Inc. | CDK inhibitors |
| CA2818046A1 (en) | 2010-11-17 | 2012-05-24 | The University Of North Carolina At Chapel Hill | Protection of renal tissues from ischemia through inhibition of the proliferative kinases cdk4 and cdk6 |
| ES2711777T3 (es) | 2011-09-14 | 2019-05-07 | Samumed Llc | Indazol-3-carboxamidas y su uso como inhibidores de la ruta de señalización de Wnt/b-catenina |
| WO2013148748A1 (en) | 2012-03-29 | 2013-10-03 | Francis Xavier Tavares | Lactam kinase inhibitors |
| PH12017500997A1 (en) | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
| SI2770994T1 (sl) | 2012-05-04 | 2020-02-28 | Samumed, Llc | 1H-pirazolo(3,4-B)piridini in njihove terapevtske uporabe |
| US20160024084A1 (en) | 2013-03-15 | 2016-01-28 | Concert Pharmaceuticals, Inc. | Deuterated palbociclib |
| WO2014144596A2 (en) * | 2013-03-15 | 2014-09-18 | G1 Therapeutics, Inc. | Transient protection of hematopoietic stem and progenitor cells against ionizing radiation |
| CN107417691B (zh) | 2013-03-15 | 2020-06-26 | G1治疗公司 | 高效的抗赘生剂和抗增生剂 |
| US9464092B2 (en) * | 2013-03-15 | 2016-10-11 | G1 Therapeutics, Inc. | Transient protection of normal cells during chemotherapy |
| ES2674361T3 (es) * | 2013-08-28 | 2018-06-29 | Novartis Ag | Combinación de un inhibidor de ALK y un inhibidor de CDK para el tratamiento de enfermedades celulares proliferativas |
| AU2014337356B2 (en) | 2013-10-15 | 2018-04-19 | Radux Devices, LLC | Securing a medical device to a valve instrument |
| WO2015069736A1 (en) | 2013-11-08 | 2015-05-14 | The Mclean Hospital Corporation | METHODS FOR EFFICIENT GENERATION OF GABAergic INTERNEURONS FROM PLURIPOTENT STEM CELLS |
| WO2015161288A1 (en) | 2014-04-17 | 2015-10-22 | G1 Therapeutics, Inc. | Tricyclic lactams for use as anti-neoplastic and anti-proliferative agents |
| WO2016015598A1 (en) * | 2014-07-26 | 2016-02-04 | Sunshine Lake Pharma Co., Ltd. | 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof |
| WO2016040185A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof |
| WO2016040184A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| WO2016040181A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| WO2016040190A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof |
| EP3191098A4 (en) | 2014-09-12 | 2018-04-25 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
| WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
| CN104610254B (zh) * | 2015-01-26 | 2017-02-01 | 新发药业有限公司 | 一种帕博赛布的低成本制备方法 |
| US10383861B2 (en) | 2015-08-03 | 2019-08-20 | Sammumed, LLC | 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
| WO2017024021A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof |
| WO2017023989A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| WO2017023980A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof |
| US10329309B2 (en) | 2015-08-03 | 2019-06-25 | Samumed, Llc | 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
| US10604512B2 (en) | 2015-08-03 | 2020-03-31 | Samumed, Llc | 3-(1H-indol-2-yl)-1H-indazoles and therapeutic uses thereof |
| WO2017024025A1 (en) | 2015-08-03 | 2017-02-09 | Sunil Kumar Kc | 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| US10285983B2 (en) | 2015-08-03 | 2019-05-14 | Samumed, Llc | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof |
| US10463651B2 (en) | 2015-08-03 | 2019-11-05 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-indazoles and therapeutic uses thereof |
| CN106565611A (zh) * | 2015-10-13 | 2017-04-19 | 华东师范大学 | 一种1-（4-环戊胺基-2-甲硫基嘧啶-5-）基乙酮的制备方法 |
| CN108473491A (zh) | 2015-11-06 | 2018-08-31 | 萨穆梅德有限公司 | 2-(1h-吲唑-3-基)-3h-咪唑并[4,5-c]吡啶以及其抗炎用途 |
| US10690673B2 (en) | 2016-03-29 | 2020-06-23 | Mayo Foundation For Medical Education And Research | Method of treating cancer metastasis by CDK 4/6 inhibitors |
| MX390577B (es) | 2016-06-01 | 2025-03-20 | Samumed Llc | Proceso de preparación de n-(5-(3-(7-(3-fluorofenil)-3h-imidazo[4,5-c]piridin-2-il)-1h-indazol-5-il)piridin-3-il)-3-metilbutanamida. |
| KR102593742B1 (ko) | 2016-10-21 | 2023-10-24 | 사뮤메드, 엘엘씨 | 인다졸-3-카복사마이드를 사용하는 방법 및 wnt/b-카테닌 신호전달 경로 억제제로서의 그들의 용도 |
| JP7630905B2 (ja) | 2016-11-07 | 2025-02-18 | バイオスプライス セラピューティクス インコーポレイテッド | 単回用量の調整済み注射用製剤 |
| KR20240024296A (ko) | 2016-12-05 | 2024-02-23 | 쥐원 쎄라퓨틱스, 인크. | 화학요법 레지멘 동안의 면역 반응의 보존 |
| MX2019008158A (es) | 2017-01-06 | 2019-12-09 | G1 Therapeutics Inc | Terapia de combinacion para el tratamiento del cancer. |
| US11395821B2 (en) | 2017-01-30 | 2022-07-26 | G1 Therapeutics, Inc. | Treatment of EGFR-driven cancer with fewer side effects |
| WO2018202866A1 (en) * | 2017-05-05 | 2018-11-08 | Fundación Para La Investigación Hospital Clínico Universitario De Valencia Incliva | Medical uses of p15/p16 agonists |
| RU2019142591A (ru) | 2017-06-29 | 2021-07-29 | Г1 Терапьютикс, Инк. | Морфологические формы g1t38 и способы их получения |
| AU2019205821C1 (en) | 2018-01-08 | 2025-02-13 | Pharmacosmos Holding A/S | G1T38 superior dosage regimes |
| HUE064843T2 (hu) | 2018-05-14 | 2024-04-28 | Pfizer | Orális oldat kiszerelés |
| SG11202101807SA (en) | 2018-08-24 | 2021-03-30 | G1 Therapeutics Inc | Improved synthesis of 1,4-diazaspiro[5.5]undecan-3-one |
| LT3849537T (lt) | 2018-09-10 | 2025-02-10 | Mirati Therapeutics, Inc. | Kompleksinės terapijos |
| US20210340502A1 (en) * | 2018-09-28 | 2021-11-04 | The Mclean Hospital Corporation | Generation of Post-Mitotic Migratory Cortical Interneurons |
| EP3797776B1 (en) | 2019-09-30 | 2025-07-23 | Universitätsmedizin Mainz | Cdk4/6 inhibitors for the treatment of psoriasis |
| US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
| AR124154A1 (es) | 2020-11-27 | 2023-02-22 | Rhizen Pharmaceuticals Ag | Inhibidores de cdk |
| WO2022149057A1 (en) | 2021-01-05 | 2022-07-14 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
| CN115364195A (zh) * | 2022-09-28 | 2022-11-22 | 中南大学湘雅二医院 | Thiostrepton在制备预防和治疗硬皮病的药物中的应用 |
| WO2025085360A1 (en) | 2023-10-16 | 2025-04-24 | The Board Of Regents Of The University Of Oklahoma | Heteroarotinoids and/or cdk4/6 inhibitors for treating human papillomavirus (hpv)-induced dysplasias, warts, and cancer in hpv-infected subjects |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5739110A (en) * | 1994-09-12 | 1998-04-14 | Biomeasure Inc. | Protection of hemopoietic cells |
| US5591855A (en) | 1994-10-14 | 1997-01-07 | Cephalon, Inc. | Fused pyrrolocarbazoles |
| US5628984A (en) | 1995-07-31 | 1997-05-13 | University Of North Carolina At Chapel Hill | Method of detecting lung disease |
| DE69839338T2 (de) | 1997-02-05 | 2008-07-10 | Warner-Lambert Company Llc | Pyrido (2,3-d) pyrimidine und 4-amino-pyrimidine als inhibitoren der zellulären proliferation |
| EP0983082A1 (en) * | 1997-05-21 | 2000-03-08 | Genentech, Inc. | Novel administration of thrombopoietin |
| GB9718913D0 (en) * | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| US6262096B1 (en) | 1997-11-12 | 2001-07-17 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
| US20040006074A1 (en) | 1998-04-28 | 2004-01-08 | The Government Of The United States Of America | Cyclin dependent kinase (CDK)4 inhibitors and their use for treating cancer |
| JP4555476B2 (ja) | 1998-06-16 | 2010-09-29 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ， アズ レプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 縮合アゼピノン型サイクリン依存性キナーゼ阻害物質 |
| CA2360671A1 (en) | 1999-01-29 | 2000-08-03 | The Board Of Trustees Of The University Of Illinois | P53 inhibitors and therapeutic use of the same |
| WO2001007411A1 (en) | 1999-07-26 | 2001-02-01 | Banyu Pharmaceutical Co., Ltd. | Biarylurea derivatives |
| US6387900B1 (en) | 1999-08-12 | 2002-05-14 | Pharmacia & Upjohn S.P.A. | 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents |
| US6291504B1 (en) * | 1999-10-20 | 2001-09-18 | Dupont Pharmaceuticals Company | Acylsemicarbazides and their uses |
| AU2072201A (en) | 1999-12-16 | 2001-06-25 | Eli Lilly And Company | Agents and methods for the treatment of proliferative diseases |
| US7053070B2 (en) | 2000-01-25 | 2006-05-30 | Warner-Lambert Company | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors |
| DK1325011T3 (da) | 2000-09-29 | 2004-08-16 | Lilly Co Eli | Fremgangsmåder og forbindelser til behandling af proliferative sygdomme |
| US6706718B2 (en) | 2000-12-01 | 2004-03-16 | Bristol-Myers Squibb Company | 3-(2,4-dimethylthiazol-5-yl)indeno[1,2-c]pyrazol-4-one derivatives and their uses |
| JP4302986B2 (ja) | 2001-02-28 | 2009-07-29 | テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション | 細胞及び組織をα，β不飽和アリールスルホンにより電離放射線から防護する方法 |
| CN101001857B (zh) * | 2002-01-22 | 2011-06-22 | 沃尼尔·朗伯有限责任公司 | 2-(吡啶-2-基氨基)-吡啶并[2,3-d]嘧啶-7-酮 |
| ITMI20021116A1 (it) | 2002-05-23 | 2003-11-24 | Santoni & C Spa | Macchina circolare per maglieria calzetteria o simile con dispositivodi comando delle platine di abbattitura |
| MXPA05007503A (es) | 2003-01-17 | 2005-09-21 | Warner Lambert Co | Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular. |
| DK1648889T3 (da) | 2003-07-11 | 2009-01-05 | Warner Lambert Co | Isethionatsalt af en selektiv CDK4-inhibitor |
| EP1740184A1 (en) | 2004-03-30 | 2007-01-10 | Pfizer Products Incorporated | Combinations of signal transduction inhibitors |
| EP1763345A2 (en) | 2004-06-18 | 2007-03-21 | GPC Biotech Inc. | Kinase inhibitors for treating cancers |
| CA2594425A1 (en) | 2005-01-14 | 2006-07-20 | Janssen Pharmaceutica N.V. | 5-membered annelated heterocyclic pyrimidines as kinase inhibitors |
| WO2006077425A1 (en) * | 2005-01-21 | 2006-07-27 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors and further antitumor agents |
| CA2631777A1 (en) | 2005-12-22 | 2007-07-05 | Wyeth | Substituted isoquinoline-1,3(2h,4h)-diones, 1-thioxo-1,4-dihydro-2h-isoquinoline-3-ones and 1,4-dihydro-3(2h)-isoquinolones and use thereof as kinase inhibitor |
| US20070270362A1 (en) * | 2006-05-18 | 2007-11-22 | The University Of Washington | Methods and compositions for prevention or treatment of inflammatory-related diseases and disorders |
| JO3235B1 (ar) | 2006-05-26 | 2018-03-08 | Astex Therapeutics Ltd | مركبات بيررولوبيريميدين و استعمالاتها |
| US8222256B2 (en) | 2006-07-05 | 2012-07-17 | Exelixis, Inc. | Methods of using IGFIR and ABL kinase modulators |
| WO2008050836A1 (en) * | 2006-10-25 | 2008-05-02 | Ajinomoto Co., Inc. | Agent for ameliorating adverse side-effect of chemotherapeutic agent |
| JP2010513317A (ja) | 2006-12-14 | 2010-04-30 | パナシー ファーマシューティカルズ インコーポレーティッド | サイクリン依存性キナーゼの阻害による神経保護方法 |
| BRPI0720635A2 (pt) | 2006-12-22 | 2014-01-07 | Novartis Ag | Compostos orgânicos e seus usos |
| JP2010523582A (ja) * | 2007-04-03 | 2010-07-15 | バイオジェネリクス アクチェンゲゼルシャフト | グリコｐｅｇ化ｇ−ｃｓｆを用いた治療方法 |
| WO2009061345A2 (en) | 2007-11-07 | 2009-05-14 | Cornell Research Foundation, Inc. | Targeting cdk4 and cdk6 in cancer therapy |
| BRPI0821209A2 (pt) | 2007-12-19 | 2019-09-24 | Amgen Inc | composto, composição farmacêutica, métodos de tratar câncer, para reduzir o tamanho de tumor, para tratar distúrbios, e para reduzir metástase em um tumor. |
| US8685980B2 (en) | 2008-08-22 | 2014-04-01 | Novartis Ag | Pyrrolopyrimidine compounds and their uses |
| JP2012504645A (ja) * | 2008-10-01 | 2012-02-23 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | 健康な細胞に対する電離放射線の影響を低下させる又は防止するための医薬組成物 |
| CN102231984A (zh) * | 2008-10-01 | 2011-11-02 | 北卡罗来纳大学查珀尔希尔分校 | 使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗化疗化合物的造血防护 |
| WO2010132725A2 (en) | 2009-05-13 | 2010-11-18 | The University Of North Carolina At Chapel Hill | Cyclin dependent kinase inhibitors and methods of use |
| LT2632467T (lt) | 2010-10-25 | 2016-09-12 | G1 Therapeutics, Inc. | Cdk inhibitoriai |
| CA2818046A1 (en) | 2010-11-17 | 2012-05-24 | The University Of North Carolina At Chapel Hill | Protection of renal tissues from ischemia through inhibition of the proliferative kinases cdk4 and cdk6 |
-
2010
- 2010-05-13 WO PCT/US2010/034816 patent/WO2010132725A2/en not_active Ceased
- 2010-05-13 CN CN2010800318669A patent/CN102458443A/zh active Pending
- 2010-05-13 ES ES10775575.3T patent/ES2561216T3/es active Active
- 2010-05-13 US US13/319,828 patent/US20120100100A1/en not_active Abandoned
- 2010-05-13 AU AU2010248886A patent/AU2010248886A1/en not_active Abandoned
- 2010-05-13 CA CA2761896A patent/CA2761896A1/en not_active Abandoned
- 2010-05-13 EP EP15196712.2A patent/EP3025724B1/en active Active
- 2010-05-13 EP EP10775575.3A patent/EP2429566B1/en active Active
- 2010-05-13 EP EP18181639.8A patent/EP3406260B1/en active Active
- 2010-05-13 EP EP20176318.2A patent/EP3718560A3/en not_active Withdrawn
- 2010-05-13 JP JP2012511031A patent/JP2012526850A/ja active Pending
-
2011
- 2011-11-10 IL IL216315A patent/IL216315A0/en unknown
-
2013
- 2013-12-11 US US14/103,359 patent/US9616062B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012526850A5 (OSRAM) | ||
| Zorzi et al. | A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium | |
| JP2008519047A5 (OSRAM) | ||
| Zhou et al. | Radiation-induced liver disease: beyond DNA damage | |
| Giembycz | Can the anti‐inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking? | |
| CN107205959B (zh) | 靶向在超增强子区域的转录控制的方法 | |
| RU2018108589A (ru) | Лечение рака поджелудочной железы и немелкоклеточного рака легкого ингибиторами atr | |
| JP2010507567A5 (OSRAM) | ||
| CN102481253B (zh) | 包含羟基氯喹的用于抗癌治疗的局部投药用注射剂组合物 | |
| Singh et al. | Inhaled phosphodiesterase inhibitors for the treatment of chronic obstructive pulmonary disease | |
| EP2275107A3 (en) | Combinations for the treatment of diseases involving cell proliferation | |
| Singh et al. | The potentiation of the radioprotective efficacy of two medical countermeasures, gamma-tocotrienol and amifostine, by a combination prophylactic modality | |
| US20150031701A1 (en) | Compositions and methods for preventing and treating mucositis and weight loss | |
| JP2009545620A5 (OSRAM) | ||
| JP2014144962A5 (OSRAM) | ||
| Lo Bello et al. | New drugs under development for COPD | |
| JP2009530295A5 (OSRAM) | ||
| MY158929A (en) | Pharmaceutical combination | |
| Sesink et al. | The AsiDNA™ decoy mimicking DSBs protects the normal tissue from radiation toxicity through a DNA-PK/p53/p21-dependent G1/S arrest | |
| ES2922284T3 (es) | Uso de una dieta que simula el ayuno para mejorar la eficacia de los antiestrógenos en terapia contra el cáncer | |
| Wu et al. | Generalized flare of pustular psoriasis induced by PEGylated interferon‐α2b therapy for chronic hepatitis C | |
| US20120196825A1 (en) | Compositions and methods for modulating the immune system | |
| JP7332589B2 (ja) | 癌を治療するためのｍｄｍ２阻害剤とｅｒｋの阻害剤との組合せ | |
| JP2011500650A5 (OSRAM) | ||
| Garufi et al. | Irinotecan and chronomodulated infusion of 5‐fluorouracil and folinic acid in the treatment of patients with advanced colorectal carcinoma: A Phase I study |